Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
UK |
|
D
|
Dalata Hotel Group PLC
F:DHG
|
IE |
|
M
|
Maxar Technologies Inc
TSX:MAXR
|
US |
|
Catella AB
F:SKVB
|
SE |
|
J
|
Jiangnan Mould & Plastic Technology Co Ltd
SZSE:000700
|
CN |
|
Lojas Quero-Quero SA
BOVESPA:LJQQ3
|
BR |
|
T
|
Thrace Plastics Holding and Commercial SA
ATHEX:PLAT
|
GR |
|
C
|
Company K Partners Ltd
KOSDAQ:307930
|
KR |
|
C
|
Cheetah Holdings Bhd
KLSE:CHEETAH
|
MY |
|
LG Balakrishnan & Bros Ltd
NSE:LGBBROSLTD
|
IN |
|
Arovella Therapeutics Ltd
ASX:ALA
|
AU |
|
Chemours Co
NYSE:CC
|
US |
|
Sharda Cropchem Ltd
NSE:SHARDACROP
|
IN |
|
F
|
Fastenal Co
F:FAS
|
US |
|
Lammhults Design Group AB
STO:LAMM B
|
SE |
|
Baazeem Trading Company CJSC
SAU:4051
|
SA |
|
Enervit SpA
MIL:ENV
|
IT |
|
New Talisman Gold Mines Ltd
NZX:NTL
|
NZ |
|
STO Express Co Ltd
SZSE:002468
|
CN |
|
Supreme Engineering Ltd
NSE:SUPREMEENG
|
IN |
|
D
|
Dadelo SA
WSE:DAD
|
PL |
|
S
|
South Malaysia Industries Bhd
KLSE:SMI
|
MY |
|
Z
|
Zhejiang Sunrise Garment Group Co Ltd
SSE:605138
|
CN |
|
Ferrovial SE
AEX:FER
|
NL |
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
Revenue Guidance: Adaptimmune issued its first annual TECELRA sales guidance, targeting $35 million to $45 million for 2025.
Q1 Sales: TECELRA generated net sales of $4 million in its first full quarter on the market.
Launch Momentum: The TECELRA launch is progressing faster than anticipated, with 28 treatment centers already accepting referrals and full network activation expected by year-end—one year ahead of plan.
Manufacturing Performance: Manufacturing success rate remains at 100% with no capacity constraints and an average turnaround of 27 days, ahead of the 30-day target.
Gross Margin: Q1 gross margin was approximately 78%, higher than the anticipated long-term average of 70%.
No Patient Denials: All patients seeking TECELRA have had payer coverage, with no denials reported to date.
Cash Position: Substantial doubt about the company’s ability to continue as a going concern remains, and cash runway is less than 12 months.
Lete-cel Progress: Launch readiness for lete-cel is on track, with rolling BLA initiation expected before year-end and anticipated approval in 2026.
